We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+64.77%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.62B
AUM Growth
+$549M
Cap. Flow
+$182M
Cap. Flow %
11.25%
Top 10 Hldgs %
48.03%
Holding
65
New
8
Increased
19
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$64.8M
2
RPTX
Repare Therapeutics
RPTX
+$62.4M
3
RCUS icon
Arcus Biosciences
RCUS
+$49.8M
4
XOMA
Xoma
XOMA
+$27.5M
5
MRUS
Merus
MRUS
+$22.4M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$46.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$29M
3
RVMD icon
Revolution Medicines
RVMD
+$18.9M
4
SWTX
SpringWorks Therapeutics
SWTX
+$17.1M
5
CALA
Calithera Biosciences, Inc
CALA
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
26
Cartesian Therapeutics
RNAC
$224M
$23.6M 1.45%
276,485
+156,169
+130% +$14.2M
STRO icon
27
Sutro Biopharma
STRO
$402M
$18.4M 1.13%
236,839
+189,291
+398% +$18.2M
OVID icon
28
Ovid Therapeutics
OVID
$418M
$17.6M 1.09%
2,392,151
+1,106,147
+86% +$5.17M
CALT
29
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$17.5M 1.08%
+750,000
New +$14.9M
LITS
30
Lite Strategy Inc
LITS
$32.8M
$17.1M 1.05%
206,508
-45,806
-18% -$2.78M
BDTX icon
31
Black Diamond Therapeutics
BDTX
$95.1M
$16M 0.98%
378,788
– –
INFI
32
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$15.8M 0.97%
17,426,968
– –
FBRX icon
33
Forte Biosciences
FBRX
$1.57B
$14.3M 0.88%
+39,154
New +$17.5M
CDTX
34
DELISTED
Cidara Therapeutics
CDTX
$13.6M 0.84%
184,460
-6,806
-4% -$441K
SURF
35
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$13.4M 0.82%
2,038,528
+1,055,477
+107% +$3.81M
EPIX
36
DELISTED
ESSA Pharma
EPIX
$12.3M 0.76%
1,984,889
-435,676
-18% -$2.07M
PHAT icon
37
Phathom Pharmaceuticals
PHAT
$755M
$10.6M 0.65%
322,098
-354,463
-52% -$13.6M
CFRX
38
DELISTED
ContraFect Corporation
CFRX
$10.2M 0.63%
+20,000
New +$9.82M
GMDA
39
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$9.8M 0.6%
2,143,667
+1,143,667
+114% +$5.25M
PVLA
40
Palvella Therapeutics
PVLA
$2.04B
$9.66M 0.6%
38,942
-34,468
-47% -$8.06M
XFOR icon
41
X4 Pharmaceuticals
XFOR
$372M
$9.42M 0.58%
33,696
-5,362
-14% -$1.47M
VSTM icon
42
Verastem
VSTM
$496M
$8.65M 0.53%
419,083
-108,333
-21% -$2.87M
GLMD icon
43
Galmed Pharmaceuticals
GLMD
$4.96M
$8.6M 0.53%
9,998
-182
-2% -$154K
CTIC
44
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$8.04M 0.5%
6,929,690
– –
SPRO icon
45
Spero Therapeutics
SPRO
$68.3M
$6.58M 0.41%
486,540
-76,853
-14% -$863K
EVLO
46
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$6.37M 0.39%
+65,000
New +$5.69M
PHXM
47
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$5.26M 0.32%
62,500
– –
CRVS icon
48
Corvus Pharmaceuticals
CRVS
$1.09B
$4.74M 0.29%
1,742,112
-414,628
-19% -$1.23M
GNCA
49
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.64M 0.29%
2,018,398
-81,907
-4% -$189K
CRIS icon
50
Curis
CRIS
$9.69M
$4.42M 0.27%
+9,125
New +$3.37M
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2020 Portfolio in Review

As of Q2 2020, BVF Inc held 65 positions worth $1.62B, up 51% from $1.07B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $182M of net new capital in Q2 2020, opening 8 new positions and adding to 19 existing holdings. Its largest new stake was Repare Therapeutics: 1,944,546 shares worth $60.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $29M trimmed.

  • BVF Inc's largest Q2 2020 buy was Repare Therapeutics: 1,944,546 shares worth $60.3M.
  • BVF Inc added most to argenx in Q2 2020, an estimated $64.8M increase.
  • BVF Inc's biggest Q2 2020 reduction was Ionis Pharmaceuticals, cutting an estimated $29M.
  • BVF Inc fully exited Cytokinetics in Q2 2020, selling an estimated $46.4M.
  • BVF Inc's ten largest holdings make up 48% of its $1.62B portfolio in Q2 2020.
  • BVF Inc opened 8 new positions and closed 8 in Q2 2020.
  • BVF Inc's portfolio value rose 51% quarter-over-quarter to $1.62B.

Based on BVF Inc's 13F filing for Q2 2020, filed 14 Aug 2020.